-+ 0.00%
-+ 0.00%
-+ 0.00%

MetaVia Completes Last Patient Visit In Extended 24-Week Phase 1 Part 3A Study Of DA-1726

Benzinga·11/17/2026 13:34:13

Encouraging Preliminary Safety and Tolerability Observations in Part 3A Supported Decision to Extend Treatment from 16 to 24 Weeks